SGMO vs. MYGN, ZBIO, EBS, LXRX, RIGL, CBIO, XOMA, VNDA, VSTM, and CDXS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Crescent Biopharma (CBIO), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), and Codexis (CDXS). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs. Its Competitors
Sangamo Therapeutics (NASDAQ:SGMO) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.
Sangamo Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.
In the previous week, Sangamo Therapeutics had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 2 mentions for Sangamo Therapeutics and 1 mentions for Myriad Genetics. Sangamo Therapeutics' average media sentiment score of 0.68 beat Myriad Genetics' score of 0.63 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Sangamo Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Myriad Genetics has a net margin of -12.20% compared to Sangamo Therapeutics' net margin of -124.61%. Myriad Genetics' return on equity of -4.95% beat Sangamo Therapeutics' return on equity.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Sangamo Therapeutics presently has a consensus price target of $4.50, suggesting a potential upside of 741.12%. Myriad Genetics has a consensus price target of $14.38, suggesting a potential upside of 155.50%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Myriad Genetics.
Summary
Sangamo Therapeutics beats Myriad Genetics on 9 of the 15 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 7/3/2025 by MarketBeat.com Staff
